Clinical Trial Update: Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment [NA]

View source ↗

Summary

A randomized trial compares abiraterone acetate plus androgen deprivation therapy (APA+ADT) versus APA+ADT with local treatment in metastatic hormone-sensitive …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-sensitive Prostate Cancer

Drugs mentioned

• Zytiga (abiraterone acetate)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | NA | Status: RECRUITING